BIO 2015 Dispatches: Payer considerations, engagement key to biopharma success
This article was originally published in Scrip
Executive Summary
Too often, biopharmaceutical firms put their investment and attention mostly on research and development and gaining regulatory approval and fail to provide equal support to the commercial market access side of their businesses – which can ultimately result in a successfully approved drug being a flop in the marketplace, three expert consultants said during a 16 June session at the annual Biotechnology Industry Organization (BIO) International Conference in Philadelphia.